ArticleFrontiers in immunology2026
Immune checkpoint inhibitor-related pancreatitis with fulminant type 1 diabetes mellitus: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) are widely used in tumor therapy, and the immune-related adverse events (irAEs) they induce can involve multiple organs. As an organ with both endocrine and exocrine functions, pancreatic involvement may manifest as acute pancreatitis, new-onset diabetes mellitus, or even a combination of both. Among these, ICI-induced acute pancreatitis concurrent with fulminant type 1 diabetes mellitus (FT1DM) is extremely rare but highly critical and easily missed in clinical practice. Case presentation: A 59-year-old male patient with squamous cell carcinoma of the left base of the tongue received toripalimab combined with chemotherapy. On day 7 after treatment, he presented with nausea, vomiting, and altered mental status. Emergency examination revealed hyperglycemia (17.4 mmol/L), severe diabetic ketoacidosis (blood ketones 9.52 mmol/L, pH 7.28), and significantly elevated serum amylase (370 U/L). Abdominal CT showed swelling of the body and tail of the pancreas with surrounding exudation, consistent with acute pancreatitis. His glycated hemoglobin (HbA1c) was normal (5.4%), pancreatic autoantibodies were negative, and islet function was completely lost. He was diagnosed with toripalimab-associated acute pancreatitis (Grade 3) concurrent with FT1DM. ICIs were permanently discontinued immediately. The patient was treated with fasting, fluid replacement, somatostatin to inhibit pancreatic enzyme secretion, and intensive insulin pump therapy for glycemic control. Glucocorticoids were not administered. After 11 days of comprehensive treatment, his symptoms resolved, and he was discharged upon normalization of pancreatic enzymes and blood glucose levels. Conclusion: PD-1 inhibitors can simultaneously impair both the endocrine and exocrine functions of the pancreas, leading to the coexistence of acute pancreatitis and FT1DM. Clinicians must maintain a high index of suspicion for this dual injury. For patients receiving ICI therapy, emergency evaluation of pancreatic function is warranted once gastrointestinal symptoms or unexplained hyperglycemia/ketosis occur. Early drug withdrawal and individualized management centered on supportive care can effectively prevent life-threatening complications. Notably, this case represents the first report of such dual pancreatic injury in a patient with locally advanced tongue base squamous cell carcinoma receiving first-cycle toripalimab combined with paclitaxel plus cisplatin chemoimmunotherapy, with distinct atypical clinical manifestations and a faster steroid-free recovery trajectory compared with the single previously published toripalimab-associated case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.